lunes, 2 de octubre de 2017
Havana.- Cuban experts are evaluating the drug Heberferon to treat diseases that cause basal cell carcinoma.
In that regard, the results of administering the drug to patients suffering from Gorlin syndrome, which causes multiple basal cell carcinomas, were presented.
That disease causes the early and multiple apparition of basal cell lesions, so Heberferon might be vital to reduce the incidence of the disease and prevent recurrent surgeries.
So far, the cases treated with Heberferon show a total response to the therapy in some lesions, while the effect on others was partial and stable.
Heberferon was registered in November 2016 in Cuba's Basic Chart of Medications to treat basal cell carcinoma, the most common skin cancer.